3D graphic of CAR NK cells killing a cancer cell
3D graphic of CAR NK cells killing a cancer cell
Logo

Purified NK cells for immunotherapy: solutions for clinical-grade NK cell separation

Efficient and pure cell separation is essential to prepare donor-derived NK cells for adoptive cell therapy, from minimally manipulated products to advanced NK cell–based therapies. Our two-step clinical-grade NK cell separation depletes CD3+ cells and enriches CD56+ cells using the CliniMACS® Plus System or the CliniMACS Prodigy® Platform.

Clinical-grade NK cell separation: a pure start for immunotherapy

Natural Killer (NK) cells are a subtype of innate lymphoid cells that express the cell surface protein CD56 and lack T cell receptors (TCR) and the associated CD3 complex.1 They possess the inherent ability to recognize virally infected and tumor cells in an HLA-unrestricted manner and eliminate those targets via different cytotoxicity mechanisms.

The immunotherapeutic potential of NK cells was highlighted by observations in allogeneic T cell–depleted hematopoietic stem cell transplantation (HSCT), where alloreactive NK cells promote engraftment and the graft-versus-tumor (GVT) effect while reducing the risk of graft-versus-host disease (GVHD).2 These findings inspired the use of allogeneic NK cells in adoptive cell therapy with safety and efficacy reports in both transplant and non-transplant settings.3–6 Current NK cell–based therapies aim to enhance the anti-tumor effects of these cells through different strategies while preserving safety.

Generally, efficient separation of NK cells from leukapheresis products eliminates CD3+ T cells to prevent GVHD in allogeneic settings and selects CD56+ cells to increase the purity of the cell product.4–9

Webinar

Manufacturing of NK cells for the clinic: the Spanish experience

Dr. Antonio Perez-Martinez discusses optimizing NK cell manufacturing, the importance of a pure starting material for the final product, and the clinical evaluation of infused NK cells.

Beyond clinical-grade NK cell separation

The CliniMACS Prodigy Platform also enables the expansion of purified NK cells with the option to engineer them, for example, to generate CAR NK cells using viral vectors. The steps are automated and take place in a closed and sterile system. | Discover how the process works

Two options for clinical-grade NK cell separation

Miltenyi Biotec offers two workflows for clinical-grade NK cell isolation, one on the CliniMACS Plus and one on the CliniMACS Prodigy. The workflows on both instruments automate the depletion of CD3+ cells and optionally enrich CD56+ cells. The CliniMACS Prodigy additionally includes automated washing and labeling steps before separation to reduce hands-on time and standardize the complete procedure.

How it works

The process in both workflows begins with an initial washing step to prepare the sample. Cells are then labeled with the CliniMACS CD3 Product Line to deplete T cells. Optionally, in a second step, NK cells are enriched using the CliniMACS CD56 Product Line. This efficiently depletes T cells and minimizes B cell content, leaving a highly pure NK cell population in the final cell product.

Workflow for clinical-grade NK cell separation using the CliniMACS CD3 Product Line and the CliniMACS CD56 Product Line.

Related products for the CliniMACS PlusRelated products for the CliniMACS Prodigy
CliniMACS Plus InstrumentCliniMACS Prodigy Instrument
CliniMACS CD3 Product LineCliniMACS CD3 Product Line
CliniMACS CD56 Product LineCliniMACS CD56 Product Line
CliniMACS Depletion Tubing Set
or CliniMACS Tubing Set LS
CliniMACS Prodigy Tubing Set 320
CliniMACS Tubing Set 

Efficient performance of the CliniMACS Prodigy Platform in separating NK cells from fresh, non-mobilized leukapheresis product.

Proven efficiency in preparing NK cells for immunotherapy

The performance of clinical-grade NK cell separation on the CliniMACS Prodigy Platform is illustrated in the adjacent figure. Evaluation of the output from processing a fresh non-mobilized leukapheresis product with the two-step procedure showed a mean log depletion of 4.3 for T cells (CD3+) and 2.6 for B cells (CD19+). The overall mean recovery of NK cells was 43.4%. The isolated NK cells were highly viable (94.4%) and pure (a mean of 89.3%), and most residual non-NK cells were monocytes (a mean of 7.8%).

Training

CliniMACS Prodigy LP-3-56 user training

In a 2-day course, you learn how to automate the separation of NK cells from start to finish using the CliniMACS Prodigy. In theoretical and hands-on sessions, each process phase is discussed in detail, emphasizing user interaction and process versatility. Exercises on the instrument further deepen your practical expertise.

Learn more about our trainings

3D graphic showing blood cells passing CD34 beads for enrichment of CD34+ cells in graft engineering
Targeted T cell depletion

Seeking an alternative option for NK cell enrichment?

Targeted removal of T cells via TCRα/β or CD3 depletion combined with CD19 depletion also generates cell products enriched with NK and other therapeutically relevant cells. Our T cell depletion processes are commonly used in graft engineering but are also suitable for other applications.

Learn more

Hand supporting a person and gear icon on top of an image showing two employees working with the CliniMACS instrument in a clean room
Customized Application Services

Work with experts to customize your NK cell manufacturing

Our team in Customized Application Services helps you transform your specific NK cell manufacturing requirements into a streamlined, automated, GMP-compliant workflow ready for deployment on the CliniMACS Prodigy.

Find out more

Quality control testing by clinical flow cytometry

Researcher in clean room attire is starting an analysis on the flow cytometer MACSQuant Analyzer 16

In order to guarantee the safety and consistency of cell manufacturing, the implementation of robust in-process control and release testing (IPC/RT) is crucial.

Samples collected within the manufacturing process, e.g., on the CliniMACS Prodigy, are reliably analyzed on our standardized flow cytometry platform. Our comprehensive workflow solution comprises harmonized MACSQuant® Flow Cytometers, automated data acquisition and analysis (Express Modes) in an audit-ready software, and a broad portfolio of REAfinity® Recombinant Antibodies with superior specificity and reproducibility. Miltenyi Biotec provides comprehensive solutions with time saving and standardized staining procedures with StainExpress™ Dry Antibody Cocktails, pre-tested multicolor antibody panels, and options for cytokine multiplexing.

Selected references: how CliniMACS Instruments perform in NK cell manufacturing

Icon selected references in turquoise

Get up to speed with this selection of influential papers and reviews that show how CliniMACS Instruments are catalyzing applications with these powerful cells.

Get personalized support for your NK cell manufacturing workflow

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.

You have previously chosen International as your location.
What do you want to do?